Arcutis Biotherapeutics, Inc.
31.20USD
-1.0000 (-3.11%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ARQT.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.17▲ | $0.08 | 3 | 0 |
| Next quarter | $0.23▲ | $0.14 | 3 | 0 |
| Current year | $0.43▲ | $0.18 | 4 | 0 |
| Next year | $1.34▲ | $1.13 | 4 | 0 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.05 | $0.11 | +0.06 (+120.0%) |
| 2026-03-31 | -$0.06 | -$0.09 | -0.03 (-55.2%) |
| 2025-12-31 | $0.09 | $0.13 | +0.04 (+46.8%) |
| 2025-09-30 | -$0.09 | $0.06 | +0.15 (+163.6%) |
92 ratings from 12 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $38 $44 | Oct 19, 2026 |
| Cantor Fitzgerald | Initiated | Overweight | $48 | Oct 15, 2026 |
| Morgan Stanley | Maintained | Overweight | $34 $38 | Aug 6, 2026 |
| Guggenheim | Maintained | Buy | $35 $38 | Aug 6, 2026 |
| Needham | Maintained | Buy | $36 $40 | Aug 6, 2026 |
| Needham | Reiterated | Buy | $36 | May 7, 2026 |
| Mizuho | Maintained | Outperform | $37 $35 | Mar 2, 2026 |
| Guggenheim | Maintained | Buy | $34 $35 | Feb 27, 2026 |
| TD Cowen | Maintained | Buy | $30 $35 | Feb 26, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30 $34 | Feb 26, 2026 |
| Needham | Maintained | Buy | $31 $36 | Feb 26, 2026 |
| Needham | Maintained | Buy | $30 $31 | Jan 26, 2026 |
| Mizuho | Maintained | Outperform | $32 $37 | Nov 28, 2025 |
| Goldman Sachs | Maintained | Neutral | $19 $29 | Oct 30, 2025 |
| Needham | Maintained | Buy | $22 $30 | Oct 28, 2025 |
| Needham | Maintained | Buy | $20 $22 | Aug 7, 2025 |
| Goldman Sachs | Initiated | Neutral | $18 | Jul 25, 2025 |
| Needham | Reiterated | Buy | $20 | May 23, 2025 |
| Needham | Reiterated | Buy | $20 | Apr 9, 2025 |
| Guggenheim | Reiterated | Buy | — | Apr 3, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $19 | Apr 3, 2025 |
| Needham | Reiterated | Buy | $20 | Apr 3, 2025 |
| Jefferies | Maintained | Buy | $16 $19 | Mar 11, 2025 |
| Goldman Sachs | Maintained | Neutral | $13 $15 | Feb 27, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $19 | Feb 26, 2025 |
157 filings from 17 insiders · 17 buy / 21 sell over 6m
Officers and directors of ARQT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Welgus Howard G.Director | ExerciseStock Option (right to buy) | 2.3k | — | — | Oct 15, 2026 |
| Welgus Howard G.Director | ExerciseStock Option (right to buy) | 1.0k | — | — | Oct 15, 2026 |
| Welgus Howard G.Director | ExerciseStock Option (right to buy) | 822 | — | — | Oct 15, 2026 |
| Welgus Howard G.Director | Sell | 4.7k | $26.93 | $127k | Oct 15, 2026 |
| Welgus Howard G.Director | Exercise | 2.3k | $8.63 | $19k | Oct 15, 2026 |
| Welgus Howard G.Director | Exercise | 1.0k | $7.51 | $8k | Oct 15, 2026 |
| Welgus Howard G.Director | Exercise | 822 | $6.52 | $5k | Oct 15, 2026 |
| WELGUS HOWARD GDirector | Exercise | 4.1k | $6.52 | $32k | Sep 15, 2026 |
| WELGUS HOWARD GDirector | Sell | 4.7k | $24.18 | $114k | Sep 15, 2026 |
| MATSUDA MASARUOfficer | Sell | 10.0k | $25.03 | $250k | Sep 8, 2026 |
| CURRAN TERRIEDirector | Exercise | 38.2k | $7.51 | $317k | Aug 27, 2026 |
| CURRAN TERRIEDirector | Sell | 38.2k | $25.03 | $956k | Aug 27, 2026 |
| CURRAN TERRIEDirector | Exercise | 1.1k | $7.51 | $8k | Aug 20, 2026 |
| CURRAN TERRIEDirector | Sell | 1.1k | $26.04 | $28k | Aug 20, 2026 |
| BURNETT PATRICKOfficer | Sell | 1.7k | $27.00 | $46k | Aug 19, 2026 |
| WELGUS HOWARD GDirector | Exercise | 4.1k | $6.52 | $32k | Aug 17, 2026 |
| WELGUS HOWARD GDirector | Sell | 4.7k | $26.18 | $124k | Aug 17, 2026 |
| BURNETT PATRICKOfficer | Exercise | 15.0k | $3.64 | $55k | Aug 12, 2026 |
| BURNETT PATRICKOfficer | Sell | 15.0k | $26.08 | $395k | Aug 12, 2026 |
| BURNETT PATRICKOfficer | Sell | 955 | $26.12 | $25k | Aug 3, 2026 |
No analyst notes on ARQT yet.
Members whose judged calls on ARQT have played out most reliably.
No settled calls on ARQT yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
8 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
| 1 mo ago | 2 | 4 | 1 | 0 | 0 | Buy1.86 |
| 2 mo ago | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
| 3 mo ago | 2 | 5 | 1 | 0 | 0 | Buy1.88 |